[1] Weiss A,Lorthiois E,Barys L,Beyer KS,Bomio-Confaglia C,Burks H,Chen X,Cui X,de Kanter R,Dharmarajan L,Fedele C,Gerspacher M,Guthy DA,Head V,Jaeger A,Núñez EJ,Kearns JD,Leblanc C,Maira SM,Murphy J,Oakman H,Ostermann N,Ottl J,Rigollier P,Roman D,Schnell C,Sedrani R,Shimizu T,Stringer R,Vaupel A,Voshol H,Wessels P,Widmer T,Wilcken R,Xu K,Zecri F,Farago AF,Cotesta S,Brachmann SM.Discovery,Preclinical Characterization,and Early Clinical Activity of JDQ443,a Structurally Novel,Potent,and Selective Covalent Oral Inhibitor of KRASG12C.Cancer Discov.2022 Jun 2;12(6):1500-1517.doi:10.1158/2159-8290.CD-22-0158.PMID:35404998;PMCID:PMC9394399.